Can Pfizer's Viagra Help In Alzheimer's? Cleveland Clinic Study Shows Potential

From the Cleveland Clinic, one of the teams reports it has found a potential Alzheimer’s treatment in one of the world’s most famous drugs - Pfizer Inc’s PFE erectile dysfunction treatment Viagra (sildenafil).

  • The Cleveland Clinic researchers screened a database of 7 million patients and found that Viagra is associated with a 69% lower incidence of Alzheimer’s disease
  • Further studies using patient-derived stem cell models demonstrated that sildenafil targets tau, one of the proteins implicated in Alzheimer’s.
  • The Cleveland Clinic team used a gene-mapping network to screen about 1,600 FDA-approved drugs.
  • As part of their analysis, the Cleveland Clinic researchers compared Viagra to four other drugs - the blood pressure treatments losartan and diltiazem, and diabetes medicines metformin and glimepiride. 
  • Using the stem cell models, scientists discovered that Viagra increases the growth of brain cells and lowers the “hyperphosphorylation” of tau.
  • “Notably, we found that sildenafil use reduced the likelihood of Alzheimer’s in individuals with coronary artery disease, hypertension, and type 2 diabetes, all of which are comorbidities significantly associated with risk of the disease, as well as in those without,” said co-author Feixiong Cheng, a researcher in Cleveland Clinic’s Genomic Medicine Institute.
  • Cheng added that the Cleveland Clinic is now planning a phase 2 trial of Viagra in Alzheimer’s patients. 
  • Price Action: PFE shares are down 4.58% at $51.78 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralAlzheimer's diseaseBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!